• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Consumer Cyclical·002919.SZ
Share

Mingchen Health Co.,Ltd. Stocks

CN¥ 17.59Last Updated 14.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

CN¥ 748.21M

CN¥ 17.59
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Modest dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1994 and headquartered in Shantou, China, Mingchen Health Co., Ltd. is a key player in the Chinese personal care sector. The company's core activities involve the research, manufacturing, and distribution of a variety of personal health and hygiene products. Its offerings notably include hair care solutions such as anti-dandruff shampoos and conditioners, as well as an assortment of skincare lotions. These items are sold under a portfolio of brands, including Did Flower Show, MeiWang, YiCai, High-tech Health, Green effect, and Likoujian. The company was formerly known as Guangdong Ming Chen Co., Ltd. before its current rebranding.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 17:25

SpaceX Lost More Than $800 Billion in Market Value in a Month: Shares Are Close to Their IPO Price

14.07.2026 17:14

IBM shares plummeted 20% following a warning about weak quarterly results

14.07.2026 16:40

The second-largest U.S. bank saw a sharp increase in profits thanks to market volatility

14.07.2026 16:04

"Records Across the Board": JPMorgan Reports 41% Increase in Quarterly Profit

14.07.2026 15:48

Morning in New York: News Flow Will Drive Volatility

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026